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Clonogenic assay has been used to study the in vitro colony growth and drug sensitivity of 
human gastric and colorectal cancers. In this study, the following results were obtained: 
① Appropriate colony growth required for d巴terminingchemosensitivity (an average of 
30 or more colonies on control plates) was obtained in 51 of 104 ( 49°/o) gastric cancers and 76 of 
102 (75%) colorectal cancers. There was significant difference in colony growth between gastric 
and colorectal cancer (P<0.001). 
② Taking;;;;50% colony inhibition as a de五nitionof sensitivity in vitro, colorectal cancer 
was significantly more sensitive to the anticancer drugs used in this study than was gastric cancer 
(P<0.001). 
③ Mitomycin C showed remarkably higher e伍cacyagainst tumor colonies derived from 
colorectal cancer than against those from gastric cancer (P<0.025). 
④ Correlation of in vitro sensitivity between human tumors and corresponding xenografts 
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type I, 0. 03% (500 KU /ml) Deoxyribonuclease type 
I （以上 SigmaChemical Company, ST Louis USA) 
加 a-MEM（以下， EnzymeSolution）及び 0.035ぢ
Deoxyri bon uclease加 a-MEM（以下， DNaseSolu-
tion）を用いた．
又，腫場細胞の培養には， Penicillin(50 U /ml), St-
reptomycin (50 mcg/ml), Amphotericin-B (1. 2 mcg/ 
ml) (Gibco Laboratories, Grand island Biological 
Company), 15%牛胎児血清加 CEM(Chee’S modiι 
cation of Eagle’s medium) （以下， CultureSolution) 
を用いた．
実験室lζ移送された腫場は鋭努刃Kて充分に細切し，
腫蕩 1grあたり 10～20mlの EnzymeSolution中








Adriamyrin 0.4 (μg/ml) 
Bleomycin 2.0 
BCNU 2.0 





腫蕩細胞は cultureSolution にて suspendし， trypan
blue exclusion test lζて生細胞比率を測定した後，生
細胞数が 1.5×106/mlとなるように調整した．
Culture Solution IC Bacto-agar (Difeo Lab. De-
troit, Mich）を0.55ぢとなるように加え， 35×lOmm
の Petridish に lmlずつ分注し下層を作成した．調
整された腫蕩細胞浮遊液を lmlずつ試験管IC分注，
無制癌剤の controll～2本を除き，各々に制癌剤と







dish には 5×105個の腫蕩細胞が plateされた乙とに




原発巣 25/ 65 (38%) 
転移巣帥 26/ 39 (67 ) 
計 51/104 (49 
大腸癌
原発巣 57/ 73 (78 
転移巣柿＊ 19/ 29 (66 

















































制癌剤j 有症例胃効数＊／症癌（例銘数） 有症例大効数腸I症（癌勿例数） 
一一 一
Adriamycin 13/ 40 (33%) 19/ 67 (2896) 
BCNU 6/ 27 (22) 12/ 30 (40) 
Bleomycin 6/ 18 (33) 9/ 20 (45) 
Cis-platinum 8/ 31 (26) 21/ 47 (45) 
5-FU 14/ 43 (33) 22/ 66 (33) 
Melphalan 4/ 27 (15) 6/ 24 (25) 
Mitomycin C 9/ 47 (19) 26/ 68 (38) 







































図1 Light Microscopy, A: original human colonic cancer which was diagnosed as well 
differentiated tubular adenocarcinoma. (Hematoxylin-Eosin stain，×100), B: tu-
mor xenograft in nude mouse. The histologic picture was consistent with that of 
the original tumor. (Hematoxylin-Eosin stain，×100). 
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A: Gastric Cancer r=0.999(P<0.025) 
O: Colon Cancer r=0.989{P< 0.025) 
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